X-52813228-G-A
Position:
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_001386970.1(XAGE5):c.161G>A(p.Gly54Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000745 in 1,208,231 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 4 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.0000090 ( 0 hom., 0 hem., cov: 22)
Exomes 𝑓: 0.0000073 ( 0 hom. 4 hem. )
Consequence
XAGE5
NM_001386970.1 missense
NM_001386970.1 missense
Scores
1
2
14
Clinical Significance
Conservation
PhyloP100: -0.205
Genes affected
XAGE5 (HGNC:30930): (X antigen family member 5) This gene is a member of the XAGE subfamily, which belongs to the GAGE family. The GAGE genes are expressed in a variety of tumors and in some fetal and reproductive tissues. The protein encoded by this gene shares a sequence similarity with other GAGE/PAGE proteins. Because of the expression pattern and the sequence similarity, this protein also belongs to a family of CT (cancer-testis) antigens. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -8 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.058345407).
BS2
High Hemizygotes in GnomAdExome4 at 4 gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
XAGE5 | NM_001386970.1 | c.161G>A | p.Gly54Asp | missense_variant | 4/6 | ENST00000375501.2 | NP_001373899.1 | |
XAGE5 | NM_130775.3 | c.161G>A | p.Gly54Asp | missense_variant | 3/5 | NP_570131.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
XAGE5 | ENST00000375501.2 | c.161G>A | p.Gly54Asp | missense_variant | 4/6 | 5 | NM_001386970.1 | ENSP00000364651 | P1 | |
XAGE5 | ENST00000375503.7 | c.161G>A | p.Gly54Asp | missense_variant, NMD_transcript_variant | 2/5 | 1 | ENSP00000364653 |
Frequencies
GnomAD3 genomes AF: 0.00000898 AC: 1AN: 111297Hom.: 0 Cov.: 22 AF XY: 0.00 AC XY: 0AN XY: 33487
GnomAD3 genomes
AF:
AC:
1
AN:
111297
Hom.:
Cov.:
22
AF XY:
AC XY:
0
AN XY:
33487
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000383 AC: 7AN: 182567Hom.: 0 AF XY: 0.0000298 AC XY: 2AN XY: 67163
GnomAD3 exomes
AF:
AC:
7
AN:
182567
Hom.:
AF XY:
AC XY:
2
AN XY:
67163
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000729 AC: 8AN: 1096880Hom.: 0 Cov.: 30 AF XY: 0.0000110 AC XY: 4AN XY: 362364
GnomAD4 exome
AF:
AC:
8
AN:
1096880
Hom.:
Cov.:
30
AF XY:
AC XY:
4
AN XY:
362364
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000898 AC: 1AN: 111351Hom.: 0 Cov.: 22 AF XY: 0.00 AC XY: 0AN XY: 33551
GnomAD4 genome
AF:
AC:
1
AN:
111351
Hom.:
Cov.:
22
AF XY:
AC XY:
0
AN XY:
33551
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
2
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 03, 2024 | The c.161G>A (p.G54D) alteration is located in exon 3 (coding exon 2) of the XAGE5 gene. This alteration results from a G to A substitution at nucleotide position 161, causing the glycine (G) at amino acid position 54 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T;T
FATHMM_MKL
Benign
N
LIST_S2
Benign
T;.
M_CAP
Benign
T
MetaRNN
Benign
T;T
MetaSVM
Benign
T
MutationAssessor
Pathogenic
M;M
MutationTaster
Benign
N;N;N;N
PrimateAI
Benign
T
PROVEAN
Uncertain
D;D
REVEL
Benign
Sift
Benign
T;T
Sift4G
Benign
T;T
Polyphen
P;P
Vest4
MutPred
Gain of solvent accessibility (P = 0.0638);Gain of solvent accessibility (P = 0.0638);
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at